Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [21] HTA and Reimbursement Status of Metastatic Hormone-Sensitive Prostate Cancer, Nonmetastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
    Bencina, Goran
    Petrova, Elina
    Sonmez, Demet
    Pereira, Sonia Matos
    Dimitriadis, Ioannis
    Salomonsson, Stina
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (01): : 102 - 110
  • [22] Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other
    Alanazi, Ibrahim O.
    Al Shehri, Zafer S.
    Ebrahimie, Esmaeil
    Giahi, Hassan
    Mohammadi-Dehcheshmeh, Manijeh
    MOLECULAR CARCINOGENESIS, 2019, 58 (06) : 862 - 874
  • [23] Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Mateo, Joaquin
    Gjoerup, Ole, V
    Madison, Russell W.
    Raskina, Kira
    Tukachinsky, Hanna
    Creeden, James
    Cunningham, Rachel
    Huang, Richard S. P.
    Mata, Douglas A.
    Ross, Jeffrey S.
    Oxnard, Geoffrey R.
    Venstrom, Jeffrey M.
    Zurita, Amado J.
    EUROPEAN UROLOGY, 2022, 81 (01) : 37 - 47
  • [24] Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
    Yehya, Amani
    Ghamlouche, Fatima
    Zahwe, Amin
    Zeid, Yousef
    Wakimian, Kevork
    Mukherji, Deborah
    Abou-Kheir, Wassim
    CANCER DRUG RESISTANCE, 2022, 5 (03) : 667 - 690
  • [25] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [26] Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
    Liaw, Bobby C.
    Tsao, Che-Kai
    Seng, Sonia
    Jun, Tomi
    Gong, Yixuan
    Galsky, Matthew D.
    Oh, William K.
    ONCOLOGIST, 2022, : 366 - 367+e218
  • [27] MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
    Nickols, Nicholas G.
    Nazarian, Ramin
    Zhao, Shuang G.
    Tan, Victor
    Uzunangelov, Vladislav
    Xia, Zheng
    Baertsch, Robert
    Neeman, Elad
    Gao, Allen C.
    Thomas, George, V
    Howard, Lauren
    De Hoedt, Amanda M.
    Stuart, Josh
    Goldstein, Theodore
    Chi, Kim
    Gleave, Martin E.
    Graff, Julie N.
    Beer, Tomasz M.
    Drake, Justin M.
    Evans, Christopher P.
    Aggarwal, Rahul
    Foye, Adam
    Feng, Felix Y.
    Small, Eric J.
    Aronson, William J.
    Freedland, Stephen J.
    Witte, Owen N.
    Huang, Jiaoti
    Alumkal, Joshi J.
    Reiter, Robert E.
    Retti, Matthew B.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (04) : 531 - 538
  • [28] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [29] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [30] MANAGEMENT OF NON METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Munoz-Velez, Daniel
    ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (02): : 125 - 134
12345